MedTrace Logo

Senseye's OBCI Diagnostic Tool for PTSD

NCT05372523 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2023-04-12

No results posted yet for this study

Summary

This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study with a follow-up time point of 9 weeks post-initial intervention.

Conditions

Interventions

DIAGNOSTIC_TEST

CAPS-5 Assessment

A validated, semi-structured clinical interview to assess core PTSD symptoms

DIAGNOSTIC_TEST

Senseye OBCI

Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.

Sponsors & Collaborators

  • Senseye, Inc.

    lead INDUSTRY

Principal Investigators

  • Naser Ahmadi, MD · Olive View - UCLA

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2023-01-11
Completion
2023-01-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372523 on ClinicalTrials.gov